SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- Why You Should Play the Reflation Trade: Stock Picker

MORE HEADLINES

» Markets | Economy | Companies

- Half of Banks' Losses May Still Be Hidden: IMF Head

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Jun.10

1:28 PM ET

Tuesday, 10 Jun 2008

Is Lilly & Amylin's Byetta "Betta"?

Posted By:Mike Huckman

Topics:Stock Market | Medicine | CEOs and CFOs | Pharmaceuticals

Sectors:Insurance | Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Eli Lilly and Company | Alkermes Inc | S | Amylin Pharmaceuticals

Shares of Amylin are ambling higher today after two destructive trading days.

First, last Friday, Novo Nordisk put out a press release saying preliminary data show its drug works better than Byetta. And then, yesterday an analyst downgraded the stock just ahead of the company's long anticipated release of long-term results on its once-a-week version of Byetta.

So, today the shoe's on the other foot for NVO [NVO Loading... () ]. You can hear what AMLN CEO Dan Bradbury thinks of Novo's Friday press release in the video clip below, from his "First on CNBC" interview on "Squawk on the Street" this morning.

The stocks have changed direction after Amylin [AMLN Loading... () ], Eli Lilly [LLY Loading... () ] and Alkermes [ALKS Loading... () ] announced that after one year patients on once-a-week Byetta saw a key measure of their blood sugar level drop two percentage points and their weight go down nearly 10 pounds.

FBR biotech analyst Jim Reddoch calls the results "unprecedented." David Kliff of the "Diabetic Investor" newsletter says, ""Quite frankly the results...aren't great they're astonishing." Rodman & Renshaw's Mike King in a research note to clients writes that they're "incredibly consistent results."

But Swiss drugmaker Roche also announced test results here on a similar once-a-week product. Wachovia analyst George Farmer says Roche's drug, which is moving into late-stage studies, "emerges as a strong competitor."

Combined with Novo's test results on a one-a-day version of the same class of drug Farmer says, "We see credible competition to AMLN's (Byetta) franchise beginning to emerge by 2010."

Wachovia, FBR and R&R make a market in AMLN. FBR would also like to bank the company.

In his wrap-up ADA meeting note to subscribers today Kliff concludes, "In this heavyweight fight Novo threw everything they had at Amylin who was able to withstand the assault. In the end investors should thank the people at Novo for creating a great entry point into Amylin shares. While a bit bloody after a tough few days, Amylin remains the most valuable property in the diabetes space."

Who knew bloody fights could break out at scientific meetings?

Actos Booth
To the right of Mike is HDL or "good" cholesterol. To his left in green is a triglyceride. The photo was taken at the booth for the diabetes drug Actos on the exhibit floor at the ADA meeting at Moscone Center in San Francisco.